Quantcast

Latest Lamotrigine Stories

2010-03-04 08:30:10

CINCINNATI "“ The first comprehensive comparative effectiveness clinical trial of three widely used anti-seizure drugs for childhood absence epilepsy "“ the most common form of epilepsy in kids "“ has established an evidence-based approach for initial drug therapy. Published March 4 in the New England Journal of Medicine, data from the double-blind, randomized, comparative clinical trial fill a large information gap in the treatment of childhood absence epilepsy, also known...

2010-01-29 16:31:00

RESEARCH TRIANGLE PARK, N.C., Jan. 29 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration has approved Lamictal®XR(TM) (lamotrigine) Extended-Release Tablets as once-a-day, add-on therapy for epilepsy in patients ages 13 years and older with primary generalized tonic-clonic seizures. This is an expanded label, as Lamictal XR is approved for partial onset seizures (with or without secondary generalization) for...

2009-06-01 07:00:00

RESEARCH TRIANGLE PARK, N.C., June 1 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration has approved Lamictal(R)XR(TM) (lamotrigine) Extended-Release Tablets as once-a-day add-on therapy for epilepsy patients 13 years of age or older with partial onset seizures. Lamictal XR reduced seizures in patients who were inadequately controlled on current therapy. Lamictal XR reduced the frequency of partial seizures during a 19-week...

2009-05-11 06:00:00

- Easy-to-swallow formulation provides important new alternative for patients RESEARCH TRIANGLE PARK, N.C., May 11 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved Lamictal(R) ODT(TM) (lamotrigine) Orally Disintegrating Tablets. Lamictal ODT uses a novel drug-delivery formulation to provide Lamictal in a tablet that has a pleasant taste and disintegrates on the tongue. One factor physicians should consider...

2009-04-27 08:00:00

Lamictal Will Retain Decision Resources' Clinical Gold Standard Status for Bipolar Depression, According to a New Report from Decision Resources WALTHAM, Mass., April 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed psychiatrists identify a therapy's effect on decrease in severity of depressive symptoms as the attribute that most influences their prescribing decisions in bipolar...

77cb520a7ed78ba026994eb963c8bef81
2009-04-16 06:22:51

According to a new study, children of mothers who took the epilepsy drug valproate during pregnancy had lower IQs than children of mothers who used other anti-seizure medications. Valproate affected children had IQ scores up to nine points lower by age 3, Dr. Kimford Meador, the study's lead author, told the Associated Press. Women who could potentially bear children have long been advised to avoid valproate, also sold under the brand name Depakote, because it has previously been linked to...

2009-03-02 23:00:00

BRANFORD, Conn., March 3 /PRNewswire/ -- Marinus Pharmaceuticals, Inc. today announced that it met its primary endpoint for its Phase 2 clinical trial investigating the safety and efficacy of ganaxolone as adjunctive therapy in adults with partial onset seizures, a type of epilepsy. In this trial, ganaxolone demonstrated a statistically significant reduction in seizures versus placebo. Efficacy was seen in the first week of dosing. Ganaxolone was also found to be safe and well-tolerated in...

2009-01-28 07:00:00

PITTSBURGH, Jan. 28 /PRNewswire-FirstCall/ --Mylan Inc. (Nasdaq: MYL) today announced that its subsidiaries Mylan Pharmaceuticals Inc. and Genpharm ULC received final approvals from the U.S. Food and Drug Administration (FDA) for their Abbreviated New Drug Applications (ANDAs) for Lamotrigine Tablets. Genpharm also received final FDA approval for its ANDA for a separate Lamotrigine product, Lamotrigine Tablets Chewable Dispersible (CD). Mylan Pharmaceuticals' and Genpharm's ANDAs were...

2009-01-27 07:00:00

- Vimpat(R) demonstrated greater seizure reduction and improved seizure freedom versus placebo when added to first and second-generation antiepileptic drugs (AEDs) - Phase III study supports recent U.S. FDA and European Commission approvals of Vimpat(R) ATLANTA, Jan. 27 /PRNewswire-FirstCall/ -- The new antiepileptic drug Vimpat(R) (lacosamide) demonstrated significantly fewer seizures in adult partial-onset epilepsy patients whose seizures were inadequately controlled despite taking up to...

2009-01-07 07:00:00

UCB's Keppra XR Will Become the Gold Standard Adjunctive Treatment for Partial-Onset Epilepsy by 2012, According to a New Report from Decision Resources WALTHAM, Mass., Jan. 7 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed neurologists would welcome an adjunctive antiepileptic drug (AED) that is administered once-daily. According to U.S. neurologists, a drug of this type would...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related